Agilent to Acquire North American CDMO BIOVECTRA
Expands Agilent’s end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/
A
Based in
The acquisition builds on Agilent’s CDMO specialization in oligonucleotides and CRISPR therapeutics in three key areas:
-
Expands portfolio of services.
BIOVECTRA offers sterile fill-finish services, pDNA and mRNA capabilities, and lipid nanoparticle (LNP) formulation. -
Adds rapidly growing modalities.
BIOVECTRA brings expertise in fast-growing segments, including antibody drug conjugates (ADCs), highly potent active pharmaceutical ingredients (HPAPIs), and GLP-1. - Brings world-class capabilities to support gene editing. BIOVECTRA’s capabilities in biologics combined with Agilent’s expertise in gRNA will provide customers with a single source for gene-editing technology.
Both
“We look forward to welcoming
McDonnell continued: “Plus, BIOVECTRA’s manufacturing capabilities further expand Agilent’s end-to-end biopharma offerings into new growth vectors, including workflows that seamlessly integrate analytical instrumentation, consumables, and a wide range of lab services.”
“BIOVECTRA is excited to join Agilent, a company whose dedication to people and customers is very much aligned with ours,” said
The transaction is subject to customary closing conditions, including receipt of regulatory approvals, and is expected to close before 2025. Upon close,
About
About
Forward Looking Statements
This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, statements regarding the capabilities the acquisition brings and the assets’ future uses. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of Agilent’s customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing; and the risk that Agilent is not able to realize the savings expected from integration and restructuring activities. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that its cost-cutting initiatives will impair its ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on its operations, its markets and its ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of its supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240722078870/en/
Investor Contact
+1 408 345 8948
parmeet_ahuja@agilent.com
Media Contact
+1 408 361 0405
sarah.litton@agilent.com
Source: